Skip to main content
Top

12-05-2018 | Non-alcoholic fatty liver disease | Article

A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

Journal: Acta Diabetologica

Authors: Amedeo Lonardo, Simonetta Lugari, Stefano Ballestri, Fabio Nascimbeni, Enrica Baldelli, Mauro Maurantonio

Publisher: Springer Milan

Abstract

Evidence suggests a close relationship between nonalcoholic fatty liver disease (NAFLD) and type two diabetes (T2D). On the grounds of prevalence of disease, both conditions account for a significant financial cost for health care systems and individuals. Aim of this review article is to explore the epidemiological basis and the putative molecular mechanisms underlying the association of NAFLD with T2D. Epidemiological studies have shown that NAFLD is associated to the development of incident T2D and either reversal or improvement of NAFLD will result into decreased risk of developing incident T2D. On the other side of the coin data have shown that T2D will worsen the course of NAFLD doubling the risk of disease progression (i.e. evolution from simple steatosis to advanced fibrosis, cirrhosis, hepatocellular carcinoma, liver transplant and death). Conversely, NAFLD will contribute to metabolic decompensation of T2D. The pathogenesis of T2D in NAFLD patients may be mediated by several hepatokines impairing metabolic control. Among these, Fetuin-B, which causes glucose intolerance and is increased in patients with T2D and NAFLD with fibrosis is one of the most promising. T2D may affect the progression of NAFLD by acting at different levels of the pathogenic cascade involving gut microbiota and expanded, inflamed, dysfunctional adipose tissue. In conclusion, T2D and NAFLD are mutually, closely and bi-directionally associated. An improved understanding of molecular pathogenesis underlying this bi-directional association may allow us to be able to prevent the development of T2D by halting the progression of NAFLD.
Literature
1.
Italian Association for the Study of the Liver (AISF) (2017) AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 49:471–483CrossRef
2.
Sayiner M, Koenig A, Henry L (2016) Epidemiology of nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis 20:205–214CrossRefPubMed
3.
Nascimbeni F, Ballestri S, Machado MV et al (2018) Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev Gastroenterol Hepatol 12:351–367CrossRefPubMed
4.
Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854CrossRefPubMed
5.
Inzucchi SE (2012) Clinical practice. Diagnosis of diabetes. N Engl J Med 367:542–550CrossRefPubMed
6.
Juliana CN, Chan V, Weiping J et al (2009) Diabetes in Asia: epidemiology. Risk Factors Pathophysiol JAMA 301:2129–2140
7.
Haw JS, Galaviz KI, Straus AN et al (2017) Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 177:1808–1817CrossRefPubMedPubMedCentral
8.
Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMedPubMedCentral
9.
Dluhy RG, McMahon GT (2008) Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358:2630–2633CrossRefPubMed
10.
Ballestri S, Zona S, Targher G et al (2016) Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31:936–944CrossRefPubMed
11.
Hjellvik V, Sakshaug S, Strøm H (2012) Body mass index, triglycerides, glucose, and blood pressure as predictors of type 2 diabetes in a middle-aged Norwegian cohort of men and women. Clin Epidemiol 4:213–224CrossRefPubMedPubMedCentral
12.
Mamtani M, Kulkarni H, Dyer TD et al (2013) Waist circumference independently associates with the risk of insulin resistance and type 2 diabetes in mexican american families. PLoS One 8(3):e59153CrossRefPubMedPubMedCentral
13.
Kim SS, Cho HJ, Kim HJ et al (2018) Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis 50:370–377CrossRefPubMed
14.
Sung KC, Lee MY, Kim YH et al (2018) Obesity and incidence of diabetes: effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. Atherosclerosis 275:50–57CrossRefPubMed
15.
Lonardo A, Ballestri S, Guaraldi G et al (2016) Fatty liver is associated with an increased risk of diabetes and cardiovascular disease—evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 22:9674–9693CrossRefPubMedPubMedCentral
16.
Meisinger C, Thorand B, Schneider A et al (2002) Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med 162:82–89CrossRefPubMed
17.
Ballestri S, Nascimbeni F, Romagnoli D et al (2016) The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res 46:1074–1087CrossRefPubMed
18.
Mantovani A, Byrne CD, Bonora E et al (2018) Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 41:372–382CrossRefPubMed
19.
Enooku K, Kondo M, Fujiwara N et al (2018) Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. J Gastroenterol. https://​doi.​org/​10.​1007/​s00535-018-1472-0 PubMedPubMedCentralCrossRef
20.
Sung KC, Wild SH, Byrne CD (2013) Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 98:3637–3643CrossRefPubMed
21.
Yamazaki H, Tsuboya T, Tsuji K et al (2015) Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care 38:1673–1679CrossRefPubMed
22.
Fukuda T, Hamaguchi M, Kojima T et al (2016) Transient remission of nonalcoholic fatty liver disease decreases the risk of incident type 2 diabetes mellitus in Japanese men. Eur J Gastroenterol Hepatol 28:1443–1449CrossRefPubMed
23.
Bae JC, Kim SK, Han JM et al (2017) Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. Diabetes Res Clin Pract 129:136–143CrossRefPubMed
24.
Ballestri S, Nascimbeni F, Romagnoli D et al (2016) The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans. Adv Ther 33(3):291–319CrossRefPubMed
25.
, Lonardo A, Bellentani S, Argo CK et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997–1006CrossRefPubMed
26.
Dai W, Ye L, Liu A et al (2017) Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 96:e8179CrossRef
27.
Simeone JC, Bae JP, Hoogwerf BJ et al (2017) Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 9:679–688CrossRefPubMedPubMedCentral
28.
Pang Y, Kartsonaki C, Turnbull I et al (2018) Diabetes, plasma glucose and incidence of fatty liver, cirrhosis and liver cancer: a prospective study of 0.5 million people. Hepatology https://​doi.​org/​10.​1002/​hep.​30083 PubMedCentralCrossRefPubMed
29.
Roulot D, Costes JL, Buyck JF et al (2011) Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 60:977–984CrossRefPubMed
30.
Koehler EM, Plompen EP, Schouten JN et al (2016) Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63:138–147CrossRefPubMed
31.
Pelusi S, Petta S, Rosso C et al (2016) Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: an observational study in patients with nonalcoholic fatty liver disease. PLoS One 11(9):e0163069CrossRefPubMedPubMedCentral
32.
Caballería L, Pera G, Arteaga I et al (2018) High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol 16:1138–1145.e5CrossRefPubMed
33.
Wild SH, Walker JJ, Morling JR et al (2018) Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care 41:341–347CrossRefPubMed
34.
Zoppini G, Fedeli U, Gennaro N et al (2014) Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 109:1020–1025CrossRefPubMed
35.
Ryysy L, Häkkinen AM, Goto T et al (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749–758CrossRefPubMed
36.
Cusi K, Sanyal AJ, Zhang S et al (2017) Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab 19:1630–1634.CrossRefPubMed
37.
Patel PJ, Hossain F, Horsfall LU et al (2018) Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. J Diabetes Complications. https://​doi.​org/​10.​1016/​j.​jdiacomp.​2018.​05.​008 PubMedCrossRef
38.
Ertunc ME, Hotamisligil GS (2016) Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res 57:2099–2114CrossRefPubMedPubMedCentral
39.
Lonardo A, Targher G (2018) From a fatty liver to a sugary blood. Dig Liver Dis 50(4):378–380CrossRefPubMed
40.
Lonardo A, Nascimbeni F, Mantovani A et al (2018) Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol 68:335–352CrossRefPubMed
41.
Petersen MC, Madiraju AK, Gassaway BM et al (2016) Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J Clin Invest 126:4361–4371CrossRefPubMedPubMedCentral
42.
Goedeke L, Bates J, Vatner DF et al (2018) Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology. https://​doi.​org/​10.​1002/​hep.​30097 PubMedCrossRef
43.
Petersen MC, Shulman GI (2017) Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci 38:649–665CrossRefPubMedPubMedCentral
44.
Abderrahmani A, Yengo L, Caiazzo R et al (2018) Increased hepatic PDGF-AA signaling mediates liver insulin resistance in obesity-associated type 2 diabetes. Diabetes 67:1310–1321CrossRefPubMed
45.
Meex RCR, Watt MJ (2017) Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 13:509–520CrossRefPubMed
46.
Wang J, Yang W, Chen Z et al (2018) Long noncoding RNA lncSHGL recruits hnRNPA1 to suppress hepatic gluconeogenesis and lipogenesis. Diabetes 67:581–593CrossRefPubMed
47.
Sohail MU, Althani A, Anwar H et al (2017) Role of the gastrointestinal tract microbiome in the pathophysiology of diabetes mellitus. J Diabetes Res 2017:9631435CrossRefPubMedPubMedCentral
48.
Brunkwall L, Orho-Melander M (2017) The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. Diabetologia 60:943–951CrossRefPubMedPubMedCentral
49.
Kim JK, Kim YJ, Fillmore JJ et al (2001) Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 108:437–446CrossRefPubMedPubMedCentral
50.
Hundal RS, Petersen KF, Mayerson AB et al (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326CrossRefPubMedPubMedCentral
51.
Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445CrossRefPubMed
52.
Lee BC, Lee J (2014) Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta 1842:446–462CrossRefPubMed
53.
Dongiovanni P, Meroni M, Baselli GA et al (2017) Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clin Sci (Lond) 131:1301–1315CrossRef
54.
Barry-Hamilton V, Spangler R et al (2010) Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16:1009–1017CrossRefPubMed
55.
Meissner EG, McLaughlin M, Matthews L et al (2016) Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int 36:1783–1792CrossRefPubMedPubMedCentral
56.
Gerbes A, Zoulim F, Tilg H et al (2018) Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 67:380–388CrossRefPubMed
57.
Tao R, Wang C, Stöhr O et al (2018) Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med 24:1058–1069CrossRefPubMedPubMedCentral
58.
Meex RC, Hoy AJ, Morris A et al (2015) Fetuin B is a secreted hepatocyte factor linking steatosis to impaired glucose metabolism. Cell Metab 22:1078–1089CrossRefPubMed
59.
Haasch D, Berg C, Clampit JE et al (2006) PKC theta is a key player in the development of insulin resistance. Biochem Biophys Res Commun 343:361–368CrossRefPubMed
60.
Smith AC, Mullen KL, Junkin KA et al (2007) Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Am J Physiol Endocrinol Metab 293:E172–E181CrossRefPubMed
61.
Zabielski P, Hady HR, Chacinska M et al (2018) The effect of high fat diet and metformin treatment on liver lipids accumulation and their impact on insulin action. Sci Rep 8:7249CrossRefPubMedPubMedCentral
62.
Inoue T, Kobayashi K, Inoguchi T et al (2011) Reduced expression of adipose triglyceride lipase enhances tumor necrosis factor alpha-induced intercellular adhesion molecule-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappa B. J Biol Chem 286:32045–32053CrossRefPubMedPubMedCentral
63.
Gonzalo T, Beljaars L, van de Bovenkamp M et al (2007) Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther 321:856–865CrossRefPubMed
64.
Perumpail BJ, Cholankeril R, Yoo ER et al (2017) An overview of dietary interventions and strategies to optimize the management of non-alcoholic fatty liver disease. Diseases 5:4CrossRef
65.
Sung KC, Ryu S, Lee JY et al (2016) Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. J Hepatol 65:791–797CrossRefPubMed
66.
Snyder HS, Sakaan SA, March KL et al (2018) Non-alcoholic fatty liver disease: a review of anti-diabetic pharmacologic therapies. J Clin Transl Hepatol 6:168–174PubMedPubMedCentral
67.
Targher G, Lonardo A, Byrne CD (2018) Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 14:99–114PubMedCrossRef
68.
Lonardo A, Bellentani S, Ratziu V et al (2011) Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 5:279–289CrossRefPubMed
69.
Townsend SA, Newsome PN (2017) Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 46:494–507CrossRefPubMed
70.
Caldwell S (2017) NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol 23:103–108CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »